[GRAPHIC OMITTED][GRAPHIC OMITTED]

Media/Investors contact:
Jonathan Fassberg
The Trout Group
(212) 477-9007 x16

     CYTOGEN SELLS OWNERSHIP IN PSMA DEVELOPMENT JOINT VENTURE TO PROGENICS

    Terms include upfront cash and milestone payments to Cytogen potentially
                        totaling more than $65 million.

PRINCETON,  N.J., (APRIL 24, 2006) -- Cytogen Corporation  (NASDAQ:  CYTO) today
announced the sale of its 50% ownership interest in PSMA Development Company LLC
(PDC), the company's joint venture with Progenics Pharmaceuticals, Inc. (NASDAQ:
PGNX)  for  the  development  of  in  vivo  cancer   immunotherapies   based  on
prostate-specific membrane antigen (PSMA).

Under  the  terms of the  agreement,  Cytogen  sold its 50%  interest  in PDC to
Progenics  for an  upfront  cash  payment  of $13.2  million,  potential  future
milestone  payments totaling up to $52 million payable upon regulatory  approval
and commercialization of PDC products,  and an undisclosed royalty on future PDC
product sales.  Cytogen will no longer be responsible  for funding PDC. In 2005,
Cytogen's share of the loss associated with PDC was $3.18 million.

"PSMA is an important and broadly studied target, and the terms of our agreement
with Progenics  reflect both  companies'  recognition of the potential  value of
PSMA products," said Michael D. Becker, president and chief executive officer of
Cytogen. "Through this transaction, Cytogen realizes an attractive valuation for
its 50%  ownership  in PDC and  retains a  financial  interest  in PDC's  future
success.  In addition,  we retain the right to develop our CYT-500  radiolabeled
antibody program. The agreement also reduces Cytogen's investment in early-stage
projects and provides additional capital to support our core commercial business
strategy."

About PSMA

PSMA is a protein abundantly  expressed on the surface of prostate cancer cells,
with an increased  expression  in  high-grade  cancers,  metastatic  disease and
hormone-refractory  prostate cancer.  PSMA is also present at high levels on the
newly  formed  blood  vessels,  or  neovasculature,  needed  for the  growth and
survival of many solid tumors.  In contrast to other  prostate-related  antigens
such as  prostate-specific  antigen (PSA),  prostatic acid phosphatase (PAP) and
prostate  secretory  protein,  PSMA  is a  membrane  glycoprotein  that  is  not
secreted.  These unique  attributes make PSMA an excellent target for monoclonal
antibody  diagnostic and therapeutic  options in prostate and potentially  other
cancers.

About CYT-500

In April 2006, Cytogen announced the submission of an  Investigational  New Drug
(IND)  application to the U.S. Food and Drug  Administration  (FDA) for CYT-500,
the  company's  lead  therapeutic  candidate  targeting  PSMA.  Subject  to  FDA
acceptance and Institutional Review Board (IRB) approval at the planned clinical
site,  Cytogen expects to begin the first U.S. Phase I clinical trial of CYT-500
in patients with  hormone-refractory  prostate cancer.  CYT-500 incorporates the
same  monoclonal  antibody  utilized  in  Cytogen's   PROSTASCINT(R)   (capromab
pendetide) molecular imaging agent, but is linked to a therapeutic as opposed to
an imaging payload.  This novel product candidate is designed to enable targeted
delivery of a cytotoxic agent to PSMA-expressing cells. Cytogen retains full and
exclusive development rights to CYT-500.





ABOUT CYTOGEN CORPORATION
-------------------------

Founded in 1980,  Cytogen  Corporation of Princeton,  NJ is a  biopharmaceutical
company  dedicated to improving  the lives of patients with cancer by acquiring,
developing  and  commercializing  innovative  molecules  targeting the sites and
stages of cancer progression.  Cytogen's marketed products include  QUADRAMET(R)
(samarium Sm-153 lexidronam  injection) and PROSTASCINT(R)  (capromab pendetide)
kit for the  preparation  of Indium  In-111  capromab  pendetide  in the  United
States.   Cytogen's   development   pipeline  includes  CYT-500,  a  therapeutic
radiolabeled  antibody  targeting  prostate-specific  membrane antigen (PSMA), a
protein  highly  expressed  on the  surface  of  prostate  cancer  cells and the
neovasculature  of solid  tumors.  Cytogen  also  has  exclusive  United  States
marketing rights to COMBIDEX(R)  (ferumoxtran-10) for all applications,  and the
exclusive  right to  market  and sell  ferumoxytol  (previously  Code  7228) for
oncology applications in the United States. Full prescribing information for the
Company's products is available at  www.cytogen.com or by calling  800-833-3533.
For more  information,  please visit the Company's  website at  www.cytogen.com,
which is not part of this press release.


This press release  contains  certain  "forward-looking"  statements  within the
meaning of the Private Securities  Litigation Reform Act of 1995 and Section 21E
of the Securities Exchange Act of 1934, as amended.  All statements,  other than
statements of  historical  facts,  included in this press release  regarding our
strategy,  future operations,  financial  position,  future revenues,  projected
costs,  prospects,  plans  and  objectives  of  management  are  forward-looking
statements.  Such  forward-looking  statements  involve  a number  of risks  and
uncertainties  and investors are cautioned not to put any undue  reliance on any
forward-looking  statement.  There are a number of important  factors that could
cause  Cytogen's  results  to differ  materially  from those  indicated  by such
forward-looking  statements.  In particular,  Cytogen's business is subject to a
number of significant risks, which include,  but are not limited to: the risk of
obtaining  additional  capital;  the risk of obtaining the necessary  regulatory
approvals; the risk of whether products result from development activities;  the
risk of  shifts  in the  regulatory  environment  affecting  sales of  Cytogen's
products such as third-party  payor  reimbursement  issues;  the risk associated
with Cytogen's  dependence on its partners for development of certain  projects,
as well as other  factors  expressed  from  time to time in  Cytogen's  periodic
filings with the Securities and Exchange  Commission  (the "SEC").  As a result,
this press release should be read in conjunction with Cytogen's periodic filings
with the SEC. The forward-looking  statements  contained herein are made only as
of the date of this press  release,  and Cytogen  undertakes  no  obligation  to
publicly update such forward-looking  statements to reflect subsequent events or
circumstances.

                                       ###